Diabetes in the Elderly

Canadian Journal of Diabetes

Volumn 37, Issue SUPPL.1, 2013, Pages

  Meneilly, Graydon S ^a   Knip, Aileen ^a   Tessier, Daniel ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN; LINAGLIPTIN; LIRAGLUTIDE; LONG ACTING INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; PHOSPHODIESTERASE INHIBITOR; PIOGLITAZONE; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; THIAZIDE DIURETIC AGENT;

ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL ASSESSMENT; COGNITION; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; DEMENTIA; DEPRESSION; DIABETES MELLITUS; DIAGNOSTIC TEST; DISEASE COURSE; DISEASE PREDISPOSITION; DRUG DOSE ESCALATION; DRUG TOLERANCE; DRUG USE; DYSLIPIDEMIA; EDEMA; ELDERLY CARE; ERECTILE DYSFUNCTION; EXERCISE; FRACTURE; FUNCTIONAL STATUS; GASTROINTESTINAL DISEASE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; HYPOGLYCEMIA; INSULIN RELEASE; NURSING HOME; NUTRITION; PERSONALIZED MEDICINE; PHYSICAL ACTIVITY; RISK REDUCTION; AGED; CANADA; DIABETES MELLITUS, TYPE 2; GERIATRICS; HOME FOR THE AGED; MIDDLE AGED; PRACTICE GUIDELINE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CANADA; DIABETES MELLITUS, TYPE 2; GERIATRICS; HOMES FOR THE AGED; HUMANS; MIDDLE AGED; NURSING HOMES;

EID: 84876025263     PISSN: 14992671     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcjd.2013.01.045     Document Type: Article

References (158)

1. Tessier D., Meneilly G.S. Diabetes management in the elderly. Evidence-based Diabetes Care 2001, 370-379. BC Decker Inc, Hamilton, ON. H.C. Gerstein, R.B. Haynes (Eds.).
2. Lipska K.J., De Rekeneire N., Van Ness P.H., et al. Identifying dysglycemic states in older adults: implications of the emerging use of hemoglobin A1C. J Clin Endrocinol Metab 2010, 95:5289-5295.
3. Crandall J., Schade D., Ma Y., et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. J Gerontol A Biol Med Sci 2006, 61:1075-1081. Diabetes Prevention Program Research Group.
4. Chiasson J.L., Josse R.G., Gomis R., et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002, 359:2072-2077. STOP-NIDDM Trial Research Group.
5. Gerstein H.C., Yusuf S., Bosch J., et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet 2006, 368:1096-1105. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators.
6. DeFronzo R.A., Tripathy D., Schwenke D.C., et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med 2011, 364:1104-1115.
7. Kronsbein P., Jörgens V., Mühlhauser I., et al. Evaluation of a structured treatment and teaching programme on non-insulin-dependent diabetes. Lancet 1988, 2:1407-1411.
8. Wilson W., Pratt C. The impact of diabetes education and peer support upon weight and glycemic control of elderly persons with noninsulin dependent diabetes mellitus (NIDDM). Am J Public Health 1987, 77:634-635.
9. Braun A.K., Kubiak T., Kuntsche J., et al. SGS: a structured treatment and teaching programme for older patients with diabetes mellitus: a prospective randomized controlled multi-centre trial. Age Ageing 2009, 38:390-396.
10. Fagan P.J., Schuster A.B., Boyd C. Chronic care improvement in primary care: evaluation of an integrated pay-for-performance and practice-based care coordination program among elderly patients with diabetes. Health Serv Res 2010, 45:1763-1782.
11. McGovern M.P., Williams D.J., Hannaford P.C., et al. Introduction of a new incentive and target-based contract for family physicians in the UK: good for older patients with diabetes but less good for women?. Diabet Med 2008, 25:1083-1089.
12. Shea S., Weinstock R.S., Teresi J.A., et al. A randomized trial comparing telemedicine case management with usual care in older, ethnically diverse, medically underserved patients with diabetes mellitus: 5 year results of the IDEATel Study. J Am Med Inform Assoc 2009, 16:446-456.
13. Weinstock R.S., Teresi J.A., Goland R., et al. Glycemic control and health disparities in older ethnically diverse underserved adults with diabetes. Diabetes Care 2011, 34:274-279.
14. Trief P.M., Teresi J.A., Eimcke J.P., et al. Improvement in diabetes self-efficacy and glycaemic control using telemedicine in a sample of older, ethnically diverse individuals who have diabetes: the IDEATel project. Age Ageing 2009, 38:219-225.
15. Weinstock R.S., Brooks G., Palmas W., et al. Lessened decline in physical activity and impairment of older adults with diabetes with telemedicine and pedometer use: results from the IDEATel study. Age Ageing 2011, 40:98-105.
16. Izquierdo R., Meyer S., Starren J., et al. Detection and remediation of medically urgent situations using telemedicine case management for older patients with diabetes mellitus. Ther Clin Risk Manag 2007, 3:485-489.
17. Lim S., Kang S.M., Shin H., et al. Improved glycemic control without hypoglycemia in elderly diabetic patients using the ubiquitous health care service, a new medical information system. Diabetes Care 2011, 34:308-313.
18. Bond G.E., Burr R.L., Wolf F.M., et al. The effects of a web-based intervention on psychosocial well being among adults aged 60 and older with diabetes: a randomized trial. Diabetes Educ 2010, 36:446.
19. Bond G.E., Burr R., Wolf F.M., et al. The effects of a web-based intervention on the physical outcomes associated with diabetes among adults age 60 and older: a randomized trial. Diabetes Technol Ther 2007, 9:52-59.
20. Berg G.D., Wadhwa S. Health services outcomes for a diabetes disease management program for the elderly. Dis Manag 2007, 10:226-235.
21. Rosenweig J.L., Taitel M.S., Norman G.K., et al. Diabetes disease management in Medicare advantage reduces hospitalizations and costs. Am J Manag Care 2010, 16:e157-e162.
22. Obreli-Neto P.R., Guidoni C.M., Baldoni A.O., et al. Effect of a 36-month pharmaceutical care program on pharmacotherapy adherence in elderly diabetic and hypertensive patients. Int J Clin Pharm 2011, 33:642-649.
23. Turnbull F.M., Abraira C., Anderson R.J., et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009, 52:2288-2298.
24. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560-2572. The ADVANCE collaborative group.
25. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545-2559. The ACCORD study group.
26. Wang C.-P., Hazuda H.P. Better glycemic control is associated with maintenance of lower-extremity function over time in Mexican American and European American older adults with diabetes. Diabetes Care 2011, 34:268-273.
27. Kalyani R.R., Sauder C.D., Brancati F.L., Selvin E. Association of diabetes, comorbidities and A1c with functional disability in older adults. Diabetes Care 2010, 33:1055-1060.
28. Raz I., Ceriello A., Wilson P.W., et al. Post hoc subgroup analysis of the HEART2D Trial demonstrates lower cardiovascular risk in older patients targeting postprandial versus fasting/premeal glycemia. Diabetes Care 2011, 34:1511-1513.
29. Rizzo M.R., Marfella R., Barbieri M., et al. Relationships between daily acute glucose fluctuations and cognitive performance among aged type 2 diabetic patients. Diabetes Care 2010, 33:2169-2174.
30. Miller M.E., Bonds D.E., Gerstein H., et al. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ 2010, 340:b5444.
31. Munshi M.N., Segal A.R., Emmy Suhl E., et al. Frequent hypoglycemia among elderly patients with poor glycemic control. Arch Intern Med 2011, 171:362-364.
32. Meneilly G.S., Cheung E., Tuokko H. Counterregulatory hormone responses to hypoglycemia in the elderly patient with diabetes. Diabetes 1994, 43:403-410.
33. Bremer J.P., Jauch-Chara K., Hallschmid M., et al. Hypoglycemia unawareness in older compared with middle-aged patients with type 2 diabetes. Diabetes Care 2009, 32:1513-1517.
34. Whitmer R.A., Karter A.J., Yaffe K., et al. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA 2009, 301:1565-1572.
35. De Galan B.E., Zoungas S., Chalmers J., et al. Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the action in diabetes and vascular disease: preterax and diamicron modified release controlled evaluation (ADVANCE) trial. Diabetologia 2009, 52:2328-2336.
36. Bruce D.G., Davis W.A., Casey G.P., et al. Severe hypoglycemia and cognitive impairment in older patients with diabetes: the Freemantle Diabetes Study. Diabetologia 2009, 52:1808-1815.
37. Fried L.P., Tangen C.M., Walston J., et al. Frailty in older adults: evidence for a phenotype. J Gerontol Med Sci 2001, 56A:M146-M156.
38. Blaum C.S., Xue Q.L., Tian J., et al. Is hyperglycemia associated with frailty status in older women?. J Am Geriatr Soc 2009, 57:840-847.
39. Hubbard R.E., Andrew M.K., Fallah H., Rockwood K. Comparison of the prognostic importance of diagnosed diabetes, co-morbidity and frailty in older people. Diabet Med 2010, 27:603-606.
40. Rockwood K., Song X., MacKnight C., et al. A global clinical measure of fitness and frailty in elderly people. CMAJ 2005, 173:489-495.
41. Moorhouse P., Rockwood K. Frailty and its quantitative clinical evaluation. J R Coll Physicians Edinb 2012, 42:333-340.
42. Huang E.S., Zhang Q., Gandra N., et al. The effect of comorbid illness and functional status on the expected benefits of intensive glucose control in older patients with type 2 diabetes: a decision analysis. Ann Intern Med 2008, 149:11-19.
43. Lee S.J., Boscardin W.J., Cenzer I.S., et al. The risks and benefits of implementing glycemic control guidelines in frail older adults with diabetes mellitus. J Am Geriatr Soc 2011, 59:666-672.
44. Miller C.K., Edwards L., Kissling G., et al. Nutrition education improves metabolic outcomes among older adults with diabetes mellitus: results from a randomized controlled trial. Prev Med 2002, 34:252-259.
45. Solerte S.B., Fioravanti M., Locatelli E., et al. Improvement of blood glucose control and insulin sensitivity during a long-term (60 weeks) randomized study with amino acid dietary supplements in elderly subjects with type 2 diabetes mellitus. Am J Cardiol 2008, 101(suppl):82E-88E.
46. Leenders M., Verdijk L.B., van der Hoeven L. Prolonged leucine supplementation does not augment muscle mass or affect glycemic control in elderly type 2 diabetic men. J Nutr 2011, 141:1070-1076.
47. Madden K.M., Lockhart C., Cuff D., et al. Short-term aerobic exercise reduces arterial stiffness in older adults with type 2 diabetes, hypertension and hypercholesterolemia. Diabetes Care 2009, 32:1531-1535.
48. Madden K.M., Lockhart C., Potter T.F., Cuff D. Aerobic training restores arterial baroreflex sensitivity in older adults with 2 type diabetes, hypertension and hypercholesterolemia. Clin J Sport Med 2010, 20:312-317.
49. Tessier D., Ménard J., Fülöp T., et al. Effects of aerobic physical exercise in the elderly with type 2 diabetes mellitus. Arch Gerontol Geriatr 2000, 31:121-132.
50. Ligtenberg P.C., Godaert G.L.R., Hillenaar E.F., et al. Influence of a physical training program on psychological well being in elderly type 2 diabetes patients. Psychological well being, physical training, and type 2 diabetes [letter]. Diabetes Care 1998, 21:2196-2197.
51. Ligtenberg P.C., Hoekstra J.B.L., Bol E., et al. Effects of physical training on metabolic control in elderly type 2 diabetes mellitus patients. Clin Sci (Lond) 1997, 93:127-135.
52. Dunstan D.W., Daly R.M., Owen N., et al. High-intensity resistance training improves glycemic control in older patients with type 2 diabetes. Diabetes Care 2002, 25:1729-1736.
53. Castaneda C., Layne J.E., Munoz-Orians L., et al. A randomized controlled trial of resistance exercise training to improve glycemic control in older adults with type 2 diabetes. Diabetes Care 2002, 25:2335-2341.
54. Brandon L.J., Gaasch D.A., Boyette L.W., et al. Effects of long-term resistive training on mobility and strength in older adults with diabetes. J Gerontol A Biol Sci Med Sci 2003, 58:740-745.
55. Cuff D.J., Meneilly G.S., Martin A., et al. Effective exercise modality to reduce insulin resistance in women with type 2 diabetes. Diabetes Care 2003, 26:2977-2982.
56. Ibanez J., Izquierdo M., Argüelles I., et al. Twice-weekly progressive resistance training decreases abdominal fat and improves insulin sensitivity in older men with type 2 diabetes. Diabetes Care 2005, 28:662-667.
57. Morrison S., Colberg S.R., Mariano M., et al. Balance training reduces falls risk in older individuals with type 2 diabetes. Diabetes Care 2010, 33:748-750.
58. Song C.H., Petrofsky J.S., Lee S.W., et al. Effects of an exercise program on balance and trunk proprioception in older adults with diabetic neuropathies. Diabet Technol Ther 2011, 13:803-811.
59. Dunstan D.W., Daly R.M., Owen N., et al. Home-based resistance training is not sufficient to maintain improved glycemic control following supervised training in older individuals with type 2 diabetes. Diabetes Care 2005, 28:3-9.
60. Meneilly G.S., Elahi D. Metabolic alterations in middle-aged and elderly lean patients with type 2 diabetes. Diabetes Care 2005, 28:1498-1499.
61. Meneilly G.S., Elliott T. Metabolic alterations in middle-aged and elderly obese patients with type 2 diabetes. Diabetes Care 1999, 22:112-118.
62. Meneilly G.S., Elliott T., Tessier D., et al. NIDDM in the elderly. Diabetes Care 1996, 19:1320-1325.
63. Arner P., Pollare T., Lithell H. Different aetiologies of type 2 (non-insulin-dependent) diabetes mellitus in obese and non-obese subjects. Diabetologia 1991, 34:483-487.
64. Libby G., Donnelly L.A., Donnan P.T., et al. New users of metformin are at low risk of incident cancer. Diabetes Care 2009, 32:1620-1625.
65. Baur D.M., Klotsche J., Ole-Petter R., Hamnvik O.P.R. Type 2 diabetes mellitus and medications for type 2 diabetes mellitus are associated with risk for and mortality from cancer in a German primary care cohort. Metabolism 2011, 60:1363-1371.
66. Johnston P.S., Lebovitz H.E., Coniff R.F., et al. Advantages of alpha-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients. J Clin Endocrinol Metab 1998, 83:1515-1522.
67. Orimo H., Akiguchi I., Shiraki M. Usefulness of acarbose in the management of non-insulin-dependent diabetes in the aged. Acarbose 1982, 348-352. Excerpta Medica, New York. W. Creutzfeldt (Ed.).
68. Johansen K. Acarbose treatment of sulfonylurea-treated non-insulin dependent diabetics: a double-blind cross-over comparison of an alpha-glucosidase inhibitor with metformin. Diabet Metab 1984, 10:219-223.
69. Josse R.G., Chiasson J.L., Ryan E.A., et al. Acarbose in the treatment of elderly patients with type 2 diabetes. Diabetes Res Clin Pract 2003, 59:37-42.
70. Chilcott J., Tappenden P., Jones M.L., et al. A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus. Clin Ther 2001, 23:1792-1823.
71. Rajagopalan R., Perez A., Ye Z., et al. Pioglitazone is effective therapy for elderly patients with type 2 diabetes mellitus. Drugs Aging 2004, 21:259-271.
72. Kreider M., Heise M. Rosiglitazone in the management of older patients with type 2 diabetes mellitus. Int J Clin Pract 2002, 56:538-541.
73. Kahn S.E., Haffner S.M., Heise M.A., et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006, 355:2427-2443. ADOPT Study Group.
74. Winkelmayer W.C., Setoguchi S., Levin R., Soloman D.H. Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy. Arch Intern Med 2008, 168:2368-2375.
75. Graham D.J., Ouellet-Hellstrom R., MaCurdy T.E., et al. Risk of acute myocardial infarction, stroke, heart failure and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 2010, 304:411-418.
76. Lipscombe L.L., Gomes T., Lévesque L.E., et al. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA 2007, 298:2634-2643.
77. Home P.D., Pocock S.J., Beck-Nielsen H., et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomized, open-label trial. Lancet 2009, 373:2125-2135. RECORD Study Team.
78. Loke Y.K., Singh S., Furberg C.D. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ 2009, 180:32-39.
79. Lee C.G., Boyko E.J., Barrett-Connor E., et al. Insulin sensitizers may attenuate lean mass loss in older men with diabetes. Diabetes Care 2011, 34:2381-2386.
80. Asplund K., Wiholm B.E., Lithner F. Glibenclamide-associated hypoglycaemia: a report on 57 cases. Diabetologia 1983, 24:412-417.
81. Shorr R.I., Ray W.A., Daugherty J.R., et al. Individual sulfonylureas and serious hypoglycemia in older people. J Am Geriatr Soc 1996, 44:751-755.
82. Shorr R.I., Ray W.A., Daugherty J.R., et al. Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas. Arch Intern Med 1997, 157:1681-1686.
83. Johnsen S.P., Monster T.B., Olsen M.L., et al. Risk and short term prognosis of myocardial infarction among users of antidiabetic drugs. Am J Ther 2006, 13:134-140.
84. Greco D., Pisciotta M., Gambina F., Maggio F. Severe hypoglycaemia leading to hospital admission in type 2 diabetic patients aged 80 years or older. Exp Clin Endocrinol Diabetes 2010, 118:215-219.
85. Tessier D., Dawson K., Tétrault J.P., et al. Glibenclamide vs gliclazide in type 2 diabetes of the elderly. Diabet Med 1994, 11:974-980.
86. Holstein A., Plaschke A., Egberts E.H. Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev 2001, 17:467-473.
87. Diamicron MR once daily is effective and well tolerated in type 2 diabetes: a double-blind, randomized, multinational study. J Diabetes Complications 2000, 14:185-191. Diamicron MR Study Group.
88. Schernthaner G., Grimaldi A., Di Mario U., et al. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest 2004, 34:535-542.
89. Zeller M., Danchin N., Simon D., et al. Impact of type of preadmission sulfonylureas on mortality and cardiovascular outcomes in diabetic patients with acute myocardial infarction. J Clin Endocrinol Metab 2010, 95:4993-5002. French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction Investigators.
90. Pantalone K.M., Kattan M.W., Yu C., et al. The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy. Diabetes Care 2010, 33:1224-1229.
91. Del Prato S., Heine R.J., Keilson L., et al. Treatment of patients over 64 years of age with type 2 diabetes: experience from nateglinide pooled database retrospective analysis. Diabetes Care 2003, 26:2075-2080.
92. Papa G., Fedele V., Rizzo M.R., et al. Safety of type 2 diabetes treatment with repaglinide compared with glibenclamide in elderly people: a randomized, open-label, two-period, cross-over trial. Diabetes Care 2006, 29:1918-1920.
93. Schwartz S.L., Gerich J.E., Marcellari A., et al. Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment-naïve elderly patients with type 2 diabetes. Diabetes Obes Metab 2008, 10:652-660.
94. Schwartz S.L. Treatment of elderly patients with type 2 diabetes mellitus: a systematic review of the benefits and risks of dipeptidyl peptidase-4 inhibitors. Am J Geriatr Pharmacother 2010, 8:405-418.
95. Doucet J., Chacra A., Maheux P., et al. Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus. Curr Med Res Opin 2011, 27:863-869.
96. Barzilai N., Guo H., Mahoney E.M., et al. Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Curr Med Res Opin 2011, 27:1049-1058.
97. Chien M.N., Lee C.C., Chen W.C., et al. Effect of sitagliptin as add-on therapy in elderly type 2 diabetes patients with inadequate glycemic control in Taiwan. Int J Gerontol 2011, 5:103-106.
98. Bode B.W., Brett J., Falahati A., Pratley R.E. Comparison of the efficacy and tolerability profile of liraglutide, a once daily human GLP-1 analog in patients with type 2 diabetes ≥65 and <65 years of age: a pooled analysis from phase III studies. Am J Geriatr Pharmacother 2011, 9:423-433.
99. Trimble L.A., Sundberg S., Markham L., et al. Value of the clock drawing test to predict problems with insulin skills in older adults. Can J Diabetes 2005, 29:102-104.
100. Coscelli C., Calabrese G., Fedele D., et al. Use of premixed insulin among the elderly: reduction of errors in patient preparation of mixtures. Diabetes Care 1992, 15:1628-1630.
101. Corsi A., Torre E., Coronel G.A., et al. Pre-filled insulin pen in newly insulin-treated diabetic patients over 60 years old. Diabetes Nutr Metab 1997, 10:78-81.
102. Coscelli C., Lostia S., Lunetta M., et al. Safety, efficacy, acceptability of a pre-filled insulin pen in diabetic patients over 60 years old. Diabetes Res Clin Pract 1995, 28:173-177.
103. Herz M., Sun B., Milicevic Z., et al. Comparative efficacy of preprandial or postprandial Humalog Mix75/25 versus glyburide in patients 60 to 80 years of age with type 2 diabetes mellitus. Clin Ther 2002, 24:73-86.
104. Warren M.L., Conway M.J., Klaff L.J., et al. Postprandial versus preprandial dosing of biphasic insulin aspart in elderly type 2 diabetes patients. Diabetes Res Clin Pract 2004, 66:23-29.
105. Galic E., Vrtovec M., Bozikov V., et al. The impact of the timing of Humalog Mix25 injections on blood glucose fluctuations in the postprandial period in elderly patients with type 2 diabetes. Med Sci Monit 2005, 11:P187-P192.
106. Wolffenbuttel B.H.R., Klaff L.J., Bhushant R., et al. Initiating insulin therapy in elderly patients with type 2 diabetes: efficacy and safety of lispro mix 25 vs. basal insulin combined with oral glucose lowering agents. Diabet Med 2009, 26:1147-1155.
107. Hendra T.J., Taylor C.D. A randomized trial of insulin on well being and carrier strain in elderly type 2 diabetic subjects. J Diabetes Complications 2004, 18:148-154.
108. Aria K., Hirao K., Yamauchi M., et al. Influence of BMI, age and duration of diabetes mellitus on glycaemic control with twice-daily injections of biphasic insulin aspart 30 versus multiple daily injections of insulin aspart (JDDM 18): retrospective reanalysis of a 6-month, randomized, open-label, multicentre trial in Japan. Clin Drug Invest 2010, 30:35-40. Japanese Diabetes Clinical Data Management Study Group.
109. Herman W.H., Ilag L.L., Johnson S.L., et al. A clinical trial of continuous subcutaneous insulin infusion versus multiple daily injections in older adults with type 2 diabetes. Diabetes Care 2005, 28:1568-1573.
110. Johnson S.L., McEwan L.N., Newton C.A., et al. The impact of continuous subcutaneous insulin infusion and multiple daily injections of insulin on glucose variability in older adults with type 2 diabetes. J Diabetes Complications 2011, 25:211-215.
111. Wolffenbuttel B.H., Sels J.P., Rondas-Colbers G.J., et al. Comparison of different insulin regimens in elderly patients with NIDDM. Diabetes Care 1996, 19:1326-1332.
112. Papa G., Fedele V., Chiavetta A., et al. Therapeutic options for elderly diabetic subjects: open label, randomized clinical trial of insulin glargine added to oral antidiabetic drugs versus increased dosage of oral antidiabetic drugs. Acta Diabetol 2008, 45:53-59.
113. Janka H.U., Plewe G., Busch K. Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus. J Am Geriatr Soc 2007, 55:182-188.
114. Garber A.J., Clauson P., Pedersen C.B., Kolendorf K. Lower risk of hypoglycemia with insulin detemir than with neutral protamine Hagedorn insulin in older persons with type 2 diabetes: a pooled analysis of Phase III trials. J Am Geriatr Soc 2007, 55:1735-1740.
115. Berlie H.D., Garwood C.L. Diabetes medications related to an increased risk of falls and fall-related morbidity in the elderly. Ann Pharmacother 2010, 44:712-717.
116. Curb J.D., Pressel S.L., Cutler J.A., et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA 1996, 276:1886-1892.
117. Wang J.G., Staessen J.A., Gong L., et al. Chinese trial on isolated systolic hypertension in the elderly. Systolic Hypertension in China (Syst-China) Collaborative Group. Arch Intern Med 2000, 160:211-220.
118. Tuomilehto J., Rastenyte D., Birkenhäger W.H., et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N Engl J Med 1999, 340:677-684.
119. Lindholm L.H., Hansson L., Ekbom T., et al. Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old Patients with Hypertension-2. STOP Hypertension-2 Study Group. J Hypertens 2000, 18:1671-1675.
120. Toshiharu N., Zoungas S., Neal B., et al. Efficacy and safety of routine blood pressure lowering in older patients with diabetes: results from the ADVANCE Collaborative Group. J Hypertens 2010, 28:1141-1149.
121. Voyaki S.M., Staessen J.A., Thijs L., et al. Follow-up of renal function in treated and untreated older patients with isolated systolic hypertension. J Hypertens 2001, 19:511-519. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.
122. Barzilay J.I., Davis B.R., Bettencourt J., et al. Cardiovascular outcomes using doxazosin vs. chlorthalidone for the treatment of hypertension in older adults with and without glucose disorders: a report from the ALLHAT study. J ClinHypertens 2004, 6:116-125. ALLHAT Collaborative Research Group.
123. Rahman M., Pressel S., Davis B.R., et al. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2005, 165:936-946.
124. Whelton P.K., Barzilay J., Cushman W.C., et al. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALL-HAT). Arch Intern Med 2005, 165:1401-1409. ALLHAT Collaborative Research Group.
125. Kjeldsen S.E., Dahlöf B., Devereux R.B., et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA 2002, 288:1491-1498. LIFE (Losartan Intervention for Endpoint Reduction) Study Group.
126. Ferrari R. Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) Study. Arch Intern Med 2006, 166:659-666. Perindopril and Remodeling in Elderly with Acute Myocardial Infarction Investigators.
127. Weber M.A., Bakris G.L., Jamerson K., et al. Cardiovascular events during differing hypertension therapies in patients with diabetes. J Am Coll Cardiol 2010, 56:77-85. ACCOMPLISH Investigators.
128. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000, 355:253-259. Heart Outcomes Prevention Evaluation Study Investigators.
129. Cushman W.C., Evans G.W., Byington R.P., et al. Effects of intensive blood pressure control in type 2 diabetes mellitus. N Engl J Med 2010, 362:1575-1585.
130. McAlister F.A., Campbell N.R., Duong-Hua M., et al. Antihypertensive medication prescribing in 27,822 elderly Canadians with diabetes over the past decade. Diabetes Care 2006, 29:836-841.
131. Baigent C., Keech A., Kearney P.M., et al. Efficacy and safety of cholesterol lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins. Lancet 2005, 366:1267-1278. Cholesterol Treatment Trialists' (CTT) Collaborators.
132. Collins R., Armitage J., Parish S., et al. Effects of cholesterol lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high risk conditions. Lancet 2004, 363:757-767. Heart Protection Study Collaborative Group.
133. Collins R., Armitage J., Parish S., et al. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet 2003, 361:2005-2016. Heart Protection Study Collaborative Group.
134. The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomized placebo-controlled trial (ISRCTN48489393). BMC Med 2005, 3:6. Heart Protection Study Collaborative Group.
135. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002, 360:7-22. Heart Protection Study Collaborative Group.
136. Keech A., Colquhoun D., Best J., et al. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care 2003, 26:2713-2721. LIPID Study Group.
137. Neil H.A., DeMicco D.A., Luo D., et al. Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS). Diabetes Care 2006, 29:2378-2384. CARDS Study Investigators.
138. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002, 288:2998-3007. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group.
139. Sever P.S., Poulter N.R., Dahlöf B., et al. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial-lipid lowering arm (ASCOT-LLA). Diabetes Care 2005, 28:1151-1157.
140. Rubins H.B., Robins S.J., Collins D., et al. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med 2002, 162:2597-2604.
141. Ginsberg H.N., Elam M.B., Lovato L.C., et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010, 362:1563-1574.
142. Davis T.M.E., Ting R., Best J.D., et al. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the fenofibrate intervention and event lowering in diabetes (FIELD) study. Diabetologia 2011, 54:280-290. the FIELD Study Investigators.
143. Wagner G., Montorsi F., Auerbach S., et al. Sildenafil citrate (VIAGRA) improves erectile function in elderly patients with erectile dysfunction: a subgroup analysis. J Gerontol A Biol Sci Med Sci 2001, 56A:M113-M119.
144. Sáenz de Tejada I., Anglin G., Knight J.R., et al. Effects of tadalafil on erectile dysfunction in men with diabetes. Diabetes Care 2002, 25:2159-2164.
145. Goldstein I., Young J.M., Fischer J., et al. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care 2003, 26:777-783. Vardenafil Diabetes Study Group.
146. Bogner H.R., Morales K.H., Post E.P., Bruce M.L. A randomized controlled trial of a depression treatment program for older adults based in primary care (PROSPECT). Diabetes Care 2007, 30:3005-3010.
147. Hauner H., Kurnaz A.A., Haastert B., et al. Undiagnosed diabetes mellitus and metabolic control assessed by HbA(1c) among residents of nursing homes. Exp Clin Endocrinol Diabetes 2001, 109:326-329.
148. Sinclair A.J., Gadsby R., Penfold S., et al. Prevalence of diabetes in care home residents. Diabetes Care 2001, 24:1066-1068.
149. Aspray T.J., Nesbit K., Cassidy T.P., et al. Diabetes in British nursing and residential homes: a pragmatic screening study. Diabetes Care 2006, 29:707-708.
150. Garcia T.J., Brown S.A. Diabetes management in the nursing home: a systematic review of the literature. Diabetes Educ 2011, 37:167-187.
151. Wolffenbuttel B.H., vanVliet S., Knols A., et al. Clinical characteristics and management of diabetic patients residing in a nursing home. Diabetes Res Clin Pract 1991, 13:199-206.
152. Mooradian A.D., Osterweil D., Petrasek D., et al. Diabetes mellitus in elderly nursing home patients: a survey of clinical characteristics and management. J Am Geriatr Soc 1988, 36:391-396.
153. Dybicz S.B., Thompson S., Molotsky S., Stuart B. Prevalence of diabetes and the burden of comorbid conditions among elderly nursing home residents. Am J Geriatr Pharmacother 2011, 9:212-223.
154. Jalbert J.J., Daiellon L.A., Eaton C.B., et al. Antipsychotic use and the risk of diabetes in nursing home residents with dementia. Am J Geriatr Pharmacother 2011, 9:153-163.
155. Coulston A.M., Mandelbaum D., Reaven G.M. Dietary management of nursing home residents with non-insulin-dependent diabetes mellitus. Am J Clin Nutr 1990, 51:67-71.
156. Tariq S.H., Karcic E., Thomas D.R., et al. The use of a no-concentrated-sweets diet in the management of type 2 diabetes in nursing homes. J Am Diet Assoc 2001, 101:1463-1466.
157. Levinson Y., Epstein A., Adler B., et al. Successful use of a sucrose-containing enteral formula in diabetic nursing home elderly. Diabetes Care 2006, 29:698-700.
158. Velussi M. Lispro insulin treatment in comparison with regular human insulin in type 2 diabetic patients living in nursing homes. Diabetes Nutri Metab 2002, 15:96-100.